First U.S. Patients Receive Agili-C Implants

CartiHeal announced successful enrollment of the first two U.S. patients in the Agili-C™ Investigational Device Exemption pivotal study.

The study received FDA approval at the end of 2016. To date, in Europe and Israel, 80 patients have been enrolled and treated. The trial's objective is to demonstrate superiority of the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us